Evidence map›Paper›PMID 37805542›Full record

ArticleScientific reports2023

Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer.

Gabriela R Rossi, Ashley Jensen, Serina Ng, Zhirong Yin, Aimin Li, Anjan Misra, Daniel D Von Hoff, Lewis Gruber, Misty Gruber, Haiyong Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriela R RossiSIWA Therapeutics Inc., Chicago, IL, 60601, USA.
Ashley JensenMolecular Medicine Division, Translational Genomics Research Institute, Part of City of Hope, 445 N. Fifth St., Phoenix, AZ, 85004, USA.
Serina NgMolecular Medicine Division, Translational Genomics Research Institute, Part of City of Hope, 445 N. Fifth St., Phoenix, AZ, 85004, USA.
Zhirong YinMolecular Anatomical Pathology Cores & Biobanking Shared Resources, City of Hope, Duarte, CA, 91010, USA.
Aimin LiMolecular Anatomical Pathology Cores & Biobanking Shared Resources, City of Hope, Duarte, CA, 91010, USA.
Anjan MisraMolecular Anatomical Pathology Cores & Biobanking Shared Resources, City of Hope, Duarte, CA, 91010, USA.
Daniel D Von HoffMolecular Medicine Division, Translational Genomics Research Institute, Part of City of Hope, 445 N. Fifth St., Phoenix, AZ, 85004, USA.
Lewis GruberSIWA Therapeutics Inc., Chicago, IL, 60601, USA.
Misty GruberSIWA Therapeutics Inc., Chicago, IL, 60601, USA.
Haiyong HanMolecular Medicine Division, Translational Genomics Research Institute, Part of City of Hope, 445 N. Fifth St., Phoenix, AZ, 85004, USA. hhan@tgen.org.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

SIWA318H is a novel monoclonal antibody that selectively targets an advanced glycation end product biomarker found in damaged/dysfunctional cells exhibiting (a) aerobic glycolysis, and (b) oxidative stress. Cells with this biomarker are dysfunctional and are associated with stresses and/or damages relating to aging, cancer and other disease processes. In this study, we evaluated the biological effects and antitumor activity of SIWA318H in preclinical models for pancreatic cancer. SIWA318H binds to pancreatic cancer cells and cancer-associated fibroblasts, as well as tumor xenografts derived from pancreatic cancer patients. Furthermore, SIWA318H induced significant antibody-dependent cell-mediated cytotoxicity (ADCC) against pancreatic cancer cells. In a humanized CD34

Indexed as

Glycation End Products, AdvancedPancreatic NeoplasmsAnimalsAntibodies, MonoclonalBiomarkersCell Line, TumorHumansMiceTumor MicroenvironmentXenograft Model Antitumor AssaysAntibodies, MonoclonalBiomarkersGlycation End Products, Advanced

Identifiers

PMID37805542
PMCPMC10560265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.